Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Gut ; 51(5): 736-41, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12377816

ABSTRACT

BACKGROUND AND AIMS: Patients with preascitic liver cirrhosis display significant renal sodium retention in the upright posture and an exaggerated natriuresis during recumbency. To date, intrarenal sodium handling in these patients has not been studied using lithium clearance and fractional excretion techniques during recumbency and orthostatism. METHODS: Ten patients with preascitic (Child-Pugh A) liver cirrhosis and 10 healthy subjects underwent the following measurements during recumbency and then after four hours of standing: (a) active renin and aldosterone plasma levels; and (b) renal clearance of creatinine, sodium, potassium, and lithium (an index of fluid delivery to the loop of Henle). RESULTS: Unlike the control group, in the upright posture patients had significantly lower values of lithium clearance and fractional excretion compared with recumbency (21.6 (8.6) v 30.5 (10.2) ml/min (p<0.03) and 12.8 (4.4)% v 20.8 (4.9)% (p<0.01), respectively). Our patients showed maintenance of the glomerular-tubular balance-that is, the correlation between creatinine clearance and proximal tubular reabsorption of fluid-during both recumbency and in the upright posture (r=0.96, p<0.001; r=0.97, p<0.001, respectively). In contrast, patients displayed tubuloglomerular feedback only in the supine position. This was demonstrated by the observation of a negative correlation between lithium fractional excretion (a measure of the fractional delivery of sodium to the distal nephron) and filtered sodium load only in recumbency (r=-0.73; p< 0.03) and not during standing (r=0.22; p> 0.05). CONCLUSIONS: This study suggests that both the reduction in fluid and sodium delivery to the distal nephron and loss of tubuloglomerular feedback (the mechanism increasing glomerular filtration rate when the distal tubule is reached by a reduced sodium load) contribute towards the tendency to sodium retention in compensated cirrhosis during prolonged upright posture.


Subject(s)
Kidney/metabolism , Lithium/pharmacokinetics , Liver Cirrhosis/metabolism , Posture , Adult , Aldosterone/blood , Case-Control Studies , Creatinine/blood , Female , Humans , Kidney Glomerulus/metabolism , Kidney Tubules/metabolism , Male , Metabolic Clearance Rate , Middle Aged , Renin/blood , Sodium/blood , Statistics, Nonparametric
2.
Ann Ital Med Int ; 10(2): 93-7, 1995.
Article in Italian | MEDLINE | ID: mdl-7542466

ABSTRACT

Microsomal antigen autoantibodies are typical of type 2 autoimmune hepatitis, and a strong association with chronic hepatitis C virus (HCV) infection has been reported in certain geographical areas. These autoantibodies have been denominated LKM-1 to differentiate them from those associated with thienylic acid-induced hepatitis (LKM-2) and from those seen in patients with chronic delta hepatitis (LKM-3). To investigate the antigenic specificity of autoantibodies associated with chronic hepatitis C and delta, we analyzed 52 LKM-1 positive serum samples from patients with chronic hepatitis C and 17 LKM-3 positive serum samples from patients with chronic delta hepatitis by indirect immunofluorescence and Western blotting (immunoblotting). Reactivity of subjects with chronic hepatitis C was heterogeneous: only 5 out of 52 LKM-1 positive patients, tested by Western blot, recognized a single protein of 50 kD, previously identified by Manns et al. with an immunogenic epitope of cytochrome P450IID6. Thirteen of the 52 patients also reacted with a 70 kD microsomal protein, and 12 out of 52 reacted only with a 59 kD protein. Twenty-two sera, notwithstanding the high titer in immunofluorescence, did not evidence any reactivity when tested by Western blot. The same sera tested positive in LKM-1 ELISA when solubilized human microsomal proteins were used. Fourteen out of 17 LKM-3 positive sera from patients with chronic hepatitis delta recognized a 55 kD microsomal protein in Western blot; three sera, HCV and HIV positive, did not react with any protein by Western blot. None of these sera was positive in ELISA LKM-1.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Autoantibodies/analysis , Hepatitis C/immunology , Hepatitis D/immunology , Microsomes/immunology , Antibody Specificity , Blotting, Western , Chronic Disease , Enzyme-Linked Immunosorbent Assay , Epitopes , Female , Fluorescent Antibody Technique , Humans , Kidney/immunology , Male , Microsomes, Liver/immunology
3.
Arch Virol Suppl ; 8: 113-21, 1993.
Article in English | MEDLINE | ID: mdl-7505142

ABSTRACT

The possible relationship between essential mixed cryoglobulinemias (EMCs) and hepatitis C virus (HCV) has been investigated in eight patients with type II EMCs and biochemical signs of liver damage, whose serum tested positive in the ELISA for anti-HCV. Sera were tested using the 2nd generation RIBA assay, while serum HCV-RNA was measured semiquantitatively by a RT-PCR in whole serum, cryoprecipitates and supernatants. In all patients a percutaneous liver biopsy and a bone marrow biopsy were performed. At liver biopsy, chronic active hepatitis and/or cirrhosis were present in 6 patients; in the remaining two, a lymphoplasmacytoid infiltration of elements positive for kappa light chains was found. In all patients a bone marrow biopsy showed a paratrabecular infiltration of monoclonal lymphoplasmacytoid elements similar to those found in the liver of the two patients described above. Antibodies against structural and non-structural HCV proteins were detectable in the serum of all patients. HCV-RNA was amplified from the whole sera, cryoprecipitates and supernatants: significantly higher concentrations were found in cryoprecipitates than in supernatants. Our results confirm the high prevalence of HCV infection and ongoing viral replication in patients with type II EMC and suggest the possible implication of HCV in EMC pathogenesis.


Subject(s)
Cryoglobulinemia/complications , Hepatitis C/complications , Aged , Base Sequence , Bone Marrow/pathology , Cohort Studies , Cryoglobulinemia/pathology , DNA Primers , Follow-Up Studies , Hepatitis Antibodies/blood , Hepatitis C/epidemiology , Hepatitis C/pathology , Hepatitis C Antibodies , Humans , Liver Diseases/complications , Liver Diseases/microbiology , Liver Diseases/pathology , Middle Aged , Molecular Sequence Data , RNA, Viral/blood
4.
J Hepatol ; 11(3): 339-43, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2127054

ABSTRACT

One hundred and fifteen patients with chronic type B, D and non-A, non-B hepatitis treated with recombinant alpha-interferon were tested for six different autoantibodies prior to or during therapy, and the course of treatment was compared in autoantibody-positive and -negative patients. Three out of 25 (12%) hepatitis B patients, 14 out of 30 (47%) hepatitis D patients and 19 out of 60 (32%) chronic non-A, non-B hepatitis carriers had baseline or post-therapy autoantibodies. The rate of response between patients with and without autoantibodies among B, D and non-A, non-B patients was, respectively, 67 vs. 79%, 23 vs. 25%, 70 vs. 61% (p = N.S.). No adverse reaction was observed in the 36 patients who had or developed nuclear, smooth muscle, parietal cells and thyroid autoantibodies during therapy. A patient with baseline antibodies against liver and kidney microsomes developed an icteric acute hepatitis at the fourth month of therapy, but five other patients with this reactivity responded to therapy uneventfully. The presence of autoantibodies before therapy or their induction following therapy is not a contraindication to the use of interferon in patients with chronic viral hepatitis.


Subject(s)
Autoantibodies/immunology , Hepatitis, Viral, Human/drug therapy , Interferon Type I/therapeutic use , Animals , Chronic Disease , Fluorescent Antibody Technique , Hepatitis B/drug therapy , Hepatitis B/epidemiology , Hepatitis B/immunology , Hepatitis C/drug therapy , Hepatitis C/epidemiology , Hepatitis C/immunology , Hepatitis D/drug therapy , Hepatitis D/epidemiology , Hepatitis D/immunology , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/immunology , Humans , Interferon Type I/immunology , Italy/epidemiology , Mice , Prospective Studies , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...